Bernstein lowered the firm’s price target on Moderna (MRNA) to $45 from $55 and keeps a Market Perform rating on the shares. The firm cites the ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

The following first ran on CounterPunch at the height of the COVID pandemic in January of 2022. Are anti-vaccine ...

BRITS are being urged to stay at home and mask up when venturing outside after a “worrying” surge in norovirus cases. While ...

Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...

Events built a modular platform for organizers to bring the necessary tools to serve attendees. Their platform allows ...

We recently published a list of 9 Stocks Jim Cramer Talked About. In this article, we are going to take a look at where ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

El debate sobre el papel de las mujeres en los roles de combate, resuelto hace casi una década gracias al éxito en el mundo ...

We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...

The Trump administration has intervened in the release of important studies on the bird flu, as an outbreak escalates across ...